middle.news
Why Did EMA’s Committee Reject Trofinetide for Rett Syndrome in Europe?
9:50am on Tuesday 3rd of February, 2026 AEDT
•
Pharmaceuticals
Read Story
Why Did EMA’s Committee Reject Trofinetide for Rett Syndrome in Europe?
9:50am on Tuesday 3rd of February, 2026 AEDT
Key Points
Negative trend vote from EMA’s CHMP on trofinetide EU approval
Acadia plans to request re-examination of the opinion
Trofinetide already approved in US, Canada, and Israel
Over 1,000 patients currently treated globally
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE